Zhen Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhen Cai has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed A. Samatar
Zentalis Pharmaceuticals Inc., San Diego, California
13 shared publications - Alejandro Recio-Boiles
Department of Medicine, Hematology and Medical Oncology, The University of Arizona Comprehensive Cancer Center, Tucson, Arizona
13 shared publications - Alexandra Levy
Zentalis Pharmaceuticals, Inc., San Diego, California
13 shared publications - Daehwan Kim
Zentalis Pharmaceuticals, Inc., San Diego, California
13 shared publications - Danielle Jandial
Zentalis Pharmaceuticals, Inc., San Diego, California
13 shared publications - Deborah Blythe Doroshow
Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY
13 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S3: Study Representativeness Table
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S3: Study Representativeness Table
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S1: Evaluation of azenosertib in cellular assays.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S1: Evaluation of azenosertib in cellular assays.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S5A Distribution of cells according to cell cycle state; Supplementary Table S5B: Distribution of cells according to mitotic and cell cycle phase
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S5A Distribution of cells according to cell cycle state; Supplementary Table S5B: Distribution of cells according to mitotic and cell cycle phase
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S1: Treatment and response characteristics of selected CDX models tested with at least 60mg/kg azenosertib as single agent
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S1: Treatment and response characteristics of selected CDX models tested with at least 60mg/kg azenosertib as single agent
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S5. Additional optimization of azenosertib intermittent dosing schedule
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S5. Additional optimization of azenosertib intermittent dosing schedule
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S3. Azenosertib efficacy in solid tumor xenograft models.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S3. Azenosertib efficacy in solid tumor xenograft models.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S6: Distribution of cells according to γH2Ax status in both treatments conditions (A) or in azenosertib treated cells in different cell cycle phase (B) or mitotic (C) context for each cell lines.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S6: Distribution of cells according to γH2Ax status in both treatments conditions (A) or in azenosertib treated cells in different cell cycle phase (B) or mitotic (C) context for each cell lines.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S4: ADME, physicochemical, and pharmacokinetic properties of azenosertib.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S4: ADME, physicochemical, and pharmacokinetic properties of azenosertib.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Genomic instability and accumulation of DNA damage are hallmarks of tumor development and progression. To ensure the maintenance of genomic integrity, cells rely on a coordinated DNA damage response network that regulates cell-cycle progression, including activation of WEE1-dependent cell cycle checkpoints. If DNA damage occurs during replication, the WEE1 checkpoint is activated, thereby preventing the progression of the cell cycle. This allows damaged DNA to be repaired before cells enter mitosis, or if the damage is too extensive, induction of apoptosis. These observations have made WEE1 a promising anticancer therapeutic target. Azenosertib (ZN-c3) is a novel, selective, and orally bioavailable WEE1 inhibitor. The antiproliferative activity of azenosertib on cancer cell lines is consistent with a WEE1-dependent mechanism of action exemplified by reduction of pY15-CDK1 levels and increases in DNA damage markers. Azenosertib further exacerbates the effect of replicative stress and DNA damage by allowing cancer cells to prematurely enter mitosis, leading to mitotic catastrophe and apoptosis. Azenosertib has optimized pharmacokinetic and pharmacodynamic properties, yielding robust tumor growth inhibition in a broad range of tumor models, and is highly effective at delaying the duration of tumor regrowth after cessation of treatment. We have explored various dosing schedules in preclinical efficacy models for azenosertib that preserve antitumor activity with minimal toxicity. Phase I studies with azenosertib as monotherapy have shown preliminary clinical activity in patients with advanced solid tumors. The data presented herein support further studies of azenosertib monotherapy across multiple solid tumor indications.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Genomic instability and accumulation of DNA damage are hallmarks of tumor development and progression. To ensure the maintenance of genomic integrity, cells rely on a coordinated DNA damage response network that regulates cell-cycle progression, including activation of WEE1-dependent cell cycle checkpoints. If DNA damage occurs during replication, the WEE1 checkpoint is activated, thereby preventing the progression of the cell cycle. This allows damaged DNA to be repaired before cells enter mitosis, or if the damage is too extensive, induction of apoptosis. These observations have made WEE1 a promising anticancer therapeutic target. Azenosertib (ZN-c3) is a novel, selective, and orally bioavailable WEE1 inhibitor. The antiproliferative activity of azenosertib on cancer cell lines is consistent with a WEE1-dependent mechanism of action exemplified by reduction of pY15-CDK1 levels and increases in DNA damage markers. Azenosertib further exacerbates the effect of replicative stress and DNA damage by allowing cancer cells to prematurely enter mitosis, leading to mitotic catastrophe and apoptosis. Azenosertib has optimized pharmacokinetic and pharmacodynamic properties, yielding robust tumor growth inhibition in a broad range of tumor models, and is highly effective at delaying the duration of tumor regrowth after cessation of treatment. We have explored various dosing schedules in preclinical efficacy models for azenosertib that preserve antitumor activity with minimal toxicity. Phase I studies with azenosertib as monotherapy have shown preliminary clinical activity in patients with advanced solid tumors. The data presented herein support further studies of azenosertib monotherapy across multiple solid tumor indications.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S4. Impact of azenosertib on hematologic populations in immune competent mouse models.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S4. Impact of azenosertib on hematologic populations in immune competent mouse models.